Previous Article | Next Article 
Infection and Immunity, May 2001, p. 2821-2828, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.2821-2828.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Distribution and Kinetics of
Lipoprotein-Bound Endotoxin
J. H. M.
Levels,1,*
P. R.
Abraham,2
A.
van den
Ende,1 and
S. J. H.
van Deventer2
Department of Vascular
Medicine1 and Department of Experimental
Internal Medicine,2 Academic Medical Center,
Amsterdam, The Netherlands
Received 3 October 2000/Returned for modification 21 December
2000/Accepted 29 January 2001
 |
ABSTRACT |
Lipopolysaccharide (LPS), the major glycolipid component of
gram-negative bacterial outer membranes, is a potent endotoxin responsible for pathophysiological symptoms characteristic of infection. The observation that the majority of LPS is found in association with plasma lipoproteins has prompted the suggestion that
sequestering of LPS by lipid particles may form an integral part of a
humoral detoxification mechanism. Previous studies on the biological
properties of isolated lipoproteins used differential ultracentrifugation to separate the major subclasses. To preserve the
integrity of the lipoproteins, we have analyzed the LPS distribution, specificity, binding capacity, and kinetics of binding to lipoproteins in human whole blood or plasma by using high-performance gel permeation chromatography and fluorescent LPS of three different chemotypes. The
average distribution of O111:B4, J5, or Re595 LPS in whole blood from
10 human volunteers was 60% (±8%) high-density lipoprotein (HDL),
25% (±7%) low-density lipoprotein, and 12% (±5%) very low density
lipoprotein. The saturation capacity of lipoproteins for all three LPS
chemotypes was in excess of 200 µg/ml. Kinetic analysis however,
revealed a strict chemotype dependence. The binding of Re595 or J5 LPS
was essentially complete within 10 min, and subsequent redistribution
among the lipoprotein subclasses occurred to attain similar
distributions as O111:B4 LPS at 40 min. We conclude that under
simulated physiological conditions, the binding of LPS to lipoproteins
is highly specific, HDL has the highest binding capacity for LPS, the
saturation capacity of lipoproteins for endotoxin far exceeds the LPS
concentrations measured in clinical situations, and the kinetics of LPS
association with lipoproteins display chemotype-dependent differences.
 |
INTRODUCTION |
The lipopolysaccharide (LPS)
components of gram-negative bacterial outer membranes are potent
endotoxins responsible for hemodynamic, hematological, and metabolic
changes observed during severe infection. Activation of responsive
cells of the host immune system by low concentrations of LPS results in
the production of high levels of endogenous mediators of inflammation
such as tumor necrosis factor alpha (TNF-
) and interleukin-1
(IL-1
), IL-6, and IL-8, which are capable of sustaining the
inflammatory state. Among the observed metabolic changes in patients
are profound disturbances in plasma lipid profiles (1, 5,
14) that may also be induced in experimental animals by LPS
challenge (12). Lipid metabolism appears to be extensively
regulated during the host response to infection; however, increased
cytokine levels do not solely appear to be responsible for the
characteristic alterations in plasma lipid profiles. It has recently
been suggested that disturbances in lipid metabolism may, in fact, form
part of the host defense because the immune response is tightly linked
to the metabolic response (15). LPS binding protein (LBP)
is an acute-phase protein (29) that plays a central role
in the attenuation of the cellular response to endotoxin by the
presentation of LPS monomers to membrane-bound CD14 on monocytes and
macrophages (24, 45). On the basis of structural homology
with bactericidal permeability/increasing protein located in the
granulocytes (2), LBP together with cholesterol ester
transfer protein (CETP) and phospholipid transfer protein (PLTP) have
recently been described as belonging to a family of lipid transport
proteins (16). CETP and PLTP are known to be associated
with high-density lipoprotein (HDL) particles and to be essential for
lipoprotein remodeling (4). Recent evidence suggests that
LBP, like other members of the lipid transport family, is bound to HDL
(32, 47). A number of studies have demonstrated that LPS
binds to all of the lipoprotein classes (9, 36, 44) and
inhibits activity of proteins essential for lipoprotein homeostasis,
such as CETP, PLTP, lecithin cholesterol acyltransferase (LCAT), and
lipoprotein lipase (15). The mechanism of transfer of LPS
to reconstituted HDL particles in vitro has recently been elucidated
and shown to require LBP and soluble CD14. The rate of LPS transfer to
native lipoproteins in whole plasma appears to occur at a similar rate
but shows no soluble CD14 dependence (48).
Several observations indicate that in humans, lipid transport and
LPS-detoxifying mechanisms converge on similar routes.
Lipoprotein-bound LPS has been shown to be less biologically active in
vitro (10, 13, 27, 44). Generally, clearing of LPS from
plasma is enhanced when LPS is associated with lipoproteins and results
in increased biliary excretion (35). The rate of hepatic
clearing of LPS appears to be chemotype dependent. LPS from a bacterial
strain with a rough phenotype contains shorter O-antigenic
polysaccharide chains and is cleared more rapidly than LPS from a
smooth strain (37). Although these observations suggest
that lipoproteins constitute an endogenous LPS detoxification system
(31), the mechanism and dynamics of the association of
different LPS chemotypes with native lipoproteins, as well as the
biologic consequences of these interactions, remain to be elucidated.
The majority of LPS binding studies (27, 28, 36, 38, 44)
have used differential ultracentrifugation for the isolation of
lipoproteins and analysis of lipoprotein-bound LPS. However, a number
of studies have indicated that shear forces generated during high-speed
centrifugation results in extensive stripping of protein components of
the lipoprotein particles (8, 11, 20, 39, 46). In this
context, the relatively gentle lipoprotein separation technique of size
exclusion chromatography has been described as eminently more suitable
for maintenance of the compositional integrity of lipoproteins and associated proteins that constitute native particles (6, 23, 40,
43). Here we present the LPS binding characteristics of the
major lipoprotein classes determined with the use of high-performance gel permeation chromatography (HPGC) and three different chemotypes of
fluorescently labeled LPS. We report a comparison of the lipoprotein distribution, binding capacity, and kinetics of smooth
Escherichia coli serotype O111:B4, the rough E. coli serotype J5, and the deep rough Salmonella
enterica serovar Typhimurium Re595 LPS under simulated
physiological conditions.
 |
MATERIALS AND METHODS |
Reagents and materials.
LPS of the highest purity were
obtained from commercial sources. E. coli O111:B4 LPS was
from Sigma Chemical Co. (St. Louis, Mo.); E. coli J5 (Rc)
and Salmonella serovar Typhimurium Re595 LPS were from List
Biological Laboratories (Campbell, Calif.) or Calbiochem-Novabiochem
International (La Jolla, Calif.). Pyrogen-free distilled water, used
throughout the experiments, was from Ecotainer (Braun Medical AG,
Melsungen, Germany). The fluorescent labels 7-nitrobenz-2-oxa-1,3
diazole fluoride (NBD-F) and 4,4-difluoro-4-bora-3n,4n-diaza-S-indacene (BODIPY-R6G) were obtained from Molecular Probes Inc. (Eugene, Oreg.).
phenol 4-amino-antiperine peroxidase (PAP) reagent for postcolumn
cholesterol detection was from Bio-Merieux (Marcy l'Etoile, France).
Pyrogen-free heparin was purchased from LEO Pharmaceuticals B.V.
(Weesp, The Netherlands), and Tris was purchased from Boehringer Mannheim (Mannheim, Germany). NaCl, Tween 20, diisopropyl ether (DIPE),
and n-butanol of the highest purity were purchased from Merck (Darmstadt, Germany). TNF-
was determined with a Pelikine human TNF-
enzyme-linked immunosorbent assay kit (CLB, The
Netherlands). Centricon-100 filters were from Amicon (Beverly, Mass.).
Apolipoprotein B (apo B) and apo A-I levels of lipoprotein fractions
were measured by an automated turbidimetric assay using APA and APB
kits on an Array protein system nephelometer (Beckman, Mijdrecht, The Netherlands). NaIO4 and Purpald reagent for LPS
quantification was obtained from A1drich Sigma (Steinheim, Germany).
BODIPY labeling of O111 LPS.
Purified E. coli
O111:B4 LPS was labeled using the BODIPY-R6G oligonucleotide amine
labeling kit (Molecular Probes) by modifications of the manufacturer's
protocol for oligosaccharide labeling. LPS was prepared for labeling by
sonication of a suspension at a concentration of 2 mg/ml in
pyrogen-free water with a Branson Sonifier at maximum output for a
total of 10 min on ice. Using 12 kDa for the average size of the
O111:B4 monomer (22, 25), LPS at a final concentration of
1 mg/ml in 0.1 M sodium bicarbonate buffer (pH 8.3) was derivatized in
polypropylene tubes by addition of a fivefold molar excess of
BODIPY-R6G dissolved in dimethyl sulfoxide, and the reaction was
allowed to proceed for 2 h in the dark at room temperature. Nonconjugated BODIPY label remaining after the derivatization was
allowed to react with a 20-fold molar excess of glycine for a further
30 min. The BODIPY-LPS conjugate was separated from BODIPY-glycine by
gel filtration on a 5-ml Sephadex G15 column (Pharmacia Biotech, Inc.,
Uppsala, Sweden) using pyrogen-free water. The BODIPY-LPS micelles
elute in the void volume, while BODIPY-glycine is retained by the
matrix. The efficiency of label incorporation was determined by
measurement of the optical density at 528 nm, using the quoted
extinction coefficient of 70,000 cm
1 M
1,
and the stoichiometry of labeling was found to be approximately 1 BODIPY:1 LPS. Labeling of O111:B4 with NBD resulted in considerably lower labeling efficiencies. The concentration of the peak fraction of
labeled LPS determined by the 2-keto-3-deoxyoctulosonic acid (KDO)
assay (21) was 0.76 mg/ml.
NBD labeling of J5 and Re595 LPS.
Purified J5 or Re595 LPS
was labeled using NBD-F (Molecular Probes) according to modifications
of the manufacturer's instructions for oligosaccharides. LPS was
prepared for labeling by sonication of J5 LPS for a total of 5 min and
Re595 LPS for 2.5 min as described for O111:B4. Using 3,800 kDa (J5)
and 2,300 kDa (Re595) for the average sizes of the monomers, LPS
suspensions at 1 mg/ml in 0.1 M sodium bicarbonate buffer (pH 9.0) were
labeled by addition of a fivefold molar excess of NBD-F dissolved in
dimethyl fluoride, and the reaction was allowed to proceed in the dark
for 1 h at room temperature. Nonconjugated NBD label remaining
after the derivatization was allowed to react with a 20-fold molar
excess of glycine for a further 30 min. Derivatized NBD-LPS was
separated by gel filtration on Sephadex G15 as described above. The
efficiency of label incorporation was determined by measurement of the
optical density at 465 nm, using the quoted extinction coefficient of 8000 cm
1 M
1, and the stochiometry of
labeling found to be approximately 1 NBD: 4 J5-LPS and 1 NBD:6.5
Re595-LPS. Labeled LPS was monomerized by heating for 5 min at 100°C
in the presence of 2% (wt/vol) sodium dodecyl sulfate (SDS) and
characterized by reverse-phase high-performance liquid chromatography
on a C18 column using 20% (vol/vol) ethanol containing
0.5% (wt/vol) SDS as eluant. No free label was detected in any of the
LPS preparations. BODIPY O111:B4 eluted in four major peaks, which is
consistent with the known heterogeneity of O111:B4 (34).
By contrast, single peaks were evident for the homogeneous J5 and Re595
chemotypes. The concentrations of the peak fractions of J5 and Re595
LPS were 0.73 and 0.83 µg/ml, respectively determined by KDO assay.
LPS suspensions could be stored for up to 6 months at 4°C without
appreciable loss of fluorescence yield. Derivatization of J5 or Re595
LPS with BODIPY in our hands yielded significantly lower labeling
efficiencies compared with the NBD fluorophore. Additionally, BODIPY or
fluorescein isothiocyanate derivatives of Re595 LPS have previously
been described as having variable biological activities (41, 42,
49). We therefore chose to minimize the potential influence of
the label on the biophysical and/or biological properties of the
smaller LPS preparations (J5 and Re595) by using a fluorescent label of
lower molecular weight (NBD) for these chemotypes.
Biophysical-chemical properties of fluorescent LPS.
To
determine whether the fluorescent label influences the
biophysical-chemical behavior of derivatized LPS, competition analysis was done using samples containing mixtures of labeled and unlabeled LPS
of the same chemotype, in defined ratios from 6.25% (wt/wt) labeled
LPS:93.75% (wt/wt) unlabeled LPS to 100% (wt/wt) labeled LPS to
achieve final concentrations of 200, 300, and 200 µg/ml of plasma,
which approach saturation for O111:B4, J5, and Re595 LPS, respectively.
The volume of the LPS mixtures added to aliquots of plasma was kept
constant, and incubations were for 20 min at 37°C.
Blood sampling and handling.
Whole blood was drawn from
healthy volunteers, after informed consent, by venipuncture and
generally collected in pyrogen-free polypropylene tubes containing
heparin (2 U/ml) or in some instances tubes containing sodium citrate
(Becton Dickinson, Lincoln Park, N.J.). Blood or plasma obtained by
centrifugation (1,000 × g for 20 min at 12°C) was
always used in the experiments within 1 h after collection.
Plasma delipidation.
Total delipidation of plasma was done
essentially as described by Cham and Knowles (7). Aliquots
of 2.5 ml of fresh citrated plasma were added to 5 ml of
n-butanol-DIPE (40:60 [vol/vol]) in 14-ml polypropylene
tubes (Becton Dickinson). The mixture was gently agitated on a roller
for 30 min at room temperature and centrifuged at 1,000 × g for 10 min at room temperature for phase separation. The aqueous
phase was collected by needle puncture at the bottom of the tubes and
reextracted with 2 volumes of DIPE for 2 min. Residual butanol was
removed under vacuum at 37°C for 5 min, followed by a continuous
stream of nitrogen. Delipidated plasma was generally used immediately
for further experimentation.
Separation of the major lipoprotein classes by HPGC.
The
system contained a PU-980 ternary pump with an LG-980-02 linear
degasser, a FP-920 fluorescence detector, and UV-975 UV/VIS detector
(Jasco, Tokyo, Japan). An extra P-50 pump (Pharmacia Biotech) was used
for online cholesterol detection. The separation matrix was Superose 6 HR 10/30 (Pharmacia Biotech). The injection volume was 60 µl of
plasma diluted 1:1 with Tris-buffered saline (pH 7.4) (46)
containing 0.005% (vol/vol) Tween 20 (pH 7.4) (TBST), and the
chromatograms were developed with TBST at a continuous flow rate of
0.31 ml/min. Chromatograms were analyzed with Borwin chromatographic
software, version 1.23 (JMBS Developments, Le Fontanil, France).
Distribution, lipoprotein binding capacity, and kinetics of
different LPS chemotypes.
For the LPS distribution experiments,
50-µl aliquots of labeled LPS in saline were added to 0.5-ml portions
of fresh whole blood in polypropylene tubes to attain a concentration
of 20 to 30 µg/ml and incubated for 1 h at 37°C. For the
saturation experiments, LPS was used at concentrations in excess of 200 µg/ml. Chromatographic profiles of the association of fluorescent LPS
with lipoproteins in plasma samples were analyzed in plasma by HPGC
with fluorescence and postcolumn cholesterol detection. BODIPY-LPS was
monitored by excitation wavelength at 530 nm and emission wavelength at 550 nm; NBD-LPS was monitored at 465 and 535 nm, respectively. Cholesterol concentration in the column effluent was continuously monitored at 505 nm by enzymatic reaction with PAP reagent
(Bio-Merieux) in a reactor coil (1 m by 0.5 mm [inside diameter]) at
a flow rate of 0.1 ml/min. For the time course experiments, LPS was
added to heparinized plasma (2 U/ml) to a final concentration of 24 to
40 µg/ml and incubated for 10 to 120 min at 37°C prior to HPGC analysis. In some instances, peak fractions collected from sequential chromatographic runs were pooled and concentrated for protein analysis
using a Centricon-100 filter.
SDS-PAGE analysis of purified lipoprotein classes.
Protein
profiles of the individual lipoprotein classes isolated by HPGC were
analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) on precast
linear, 4 to 15% (wt/vol) acrylamide gradient gels containing a 4%
(wt/vol) acrylamide stacking layer (Bio-Rad, Hercules, Calif.)
(17). Lipoprotein fractions were prepared for
electrophoresis by heating for 5 min at 100°C in sample buffer consisting of 50 mM Tris (pH 6.8) containing 10% (vol/vol) glycerol, 2% (wt/vol) SDS, 0.01% (wt/vol) bromphenol blue, and 20 mM
dithiothreitol. Separation was for 1.5 h at 15 mA in
electrophoresis buffer consisting of 25 mM Tris (pH 8.3), 192 mM
glycine, and 0.1% (wt/vol) SDS. Protein bands were developed by silver
staining as described by Morrissey (26).
 |
RESULTS |
Comparison of biological activities of fluorescent LPS and
unlabeled LPS.
The biological activities of all fluorescent LPS
derivatives were compared with the activity of unlabeled LPS on the
basis of TNF-
-inducing capacity in whole blood stimulation assays. TNF-
production by labeled LPS (BODIPY-O111:B4, NBD-J5, and
NBD-Re595) in the concentration range of 1 to 1,000 ng/ml was
essentially similar to that by unlabeled LPS, within the limits of
experimental error (Fig. 1).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
Comparison of the TNF- -inducing capacity of labeled
or unlabeled O111:B4 (A), J5 (B), or Re595 (C) in whole blood from
three healthy volunteers. LPS at concentrations of 1, 10, 100, and
1,000 ng/ml of whole blood was incubated for 4 h at 37°C, and
TNF- levels were measured in duplicate. The values represent the
average ± 1 standard deviations.
|
|
Competitive analysis of labeled and unlabeled LPS.
Analysis of
lipoprotein-associated fluorescence by HPGC revealed a linear response
for all labeled LPS chemotypes (Fig. 2), indicating that no competitive inhibition by unlabeled LPS had occurred
and that the lipoprotein binding of derivatized LPS is identical to
that of unlabeled LPS.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Competition between labeled and unlabeled LPS for
binding to plasma lipoproteins. Graphs for BODIPY-O111:B4 (A), NBD-J5
(B), and NBD-Re595 (C) show the distribution of labeled LPS lipoprotein
in association with VLDL, LDL, or HDL in plasma in the presence of
unlabeled LPS for plasma concentrations approaching saturation (200, 300, and 200 µg/ml) for the three chemotypes. The LPS mixtures were
added to the plasma samples and incubated for 20 min at 37°C.
Correction was done for the natural fluorescent background of the
plasma components at the excitation and emission wavelengths used.
Linear regression was used to generate the curves.
|
|
Characterization and purity of lipoproteins separated by size
exclusion chromatography.
Total plasma lipoproteins were
completely separated into the main lipoprotein classes by HPGC on
Superose 6 as demonstrated by a typical cholesterol profile in Fig.
3A. To verify the resolution of the
separation, peak fractions were analyzed for apolipoprotein content.
Apo A-I was found exclusively in the HDL fraction, and apo B was only
detectable in the low-density and very low density lipoprotein (LDL and
VLDL) peak fractions, indicating that no cross-contamination of the
lipoprotein classes had occurred (data not shown). SDS-PAGE profiles of
the isolated HDL, LDL, and VLDL fractions revealed multiple protein
bands in addition to the normal apolipoprotein complement of each
lipoprotein class. The molecular weights of a number of major bands in
the HDL fraction, for example, correspond well with those of known
lipid-LPS transport proteins such as LCAT, CETP, LBP, and PLTP (Fig.
3B). Pooled HDL fractions were in fact shown to contain almost all of
the plasma LCAT activity (data not shown). Separation of the
lipoprotein classes by size exclusion chromatography under the
conditions described in this work yielded pure fractions containing
particles with a unique and reproducible protein profile comprising
apolipoproteins and lipid-LPS transport proteins as well as a number of
additional lipoprotein-associated proteins.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
(A) Chromatographic profile of the major plasma
lipoprotein classes separated by HPGC with online cholesterol
detection. The average molecular masses calculated from retention
characteristics were 5 MDa for VLDL, 1 MDa for LDL, and 300 kDa for
HDL. Horizontal bars indicate the lipoprotein fractions pooled for
further analysis. (B) SDS-PAGE analysis of these lipoprotein fractions
with subsequent silver staining, showing the protein composition of the
lipoproteins. M, molecular weight in thousands; lane A, VLDL; lane B,
LDL; lane C, HDL. Each well was loaded with 20 µl containing a total
of approximately 2 µg of protein.
|
|
Specificity of LPS binding.
To determine the binding
specificity of LPS for lipoproteins, we incubated equal amounts of J5
LPS with delipidated or normal plasma and determined the LPS
fluorescence profiles by HPGC (Fig. 4).
The cholesterol profile of delipidated plasma demonstrates extremely
low levels of residual cholesterol and a total absence of a typical
lipoprotein profile, indicating that delipidation was complete and that
the plasma is essentially devoid of lipid particles (Fig. 4A). The LPS
fluorescence chromatogram of lipoprotein-deficient plasma displays an
entirely different profile (Fig. 4B) and yielded approximately 5% of
the total LPS fluorescence signal for normal plasma (Fig. 4B).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 4.
Chromatographic LPS cholesterol (A) and fluorescence (B)
profiles of normal (continuous lines) and delipidated (dotted lines)
plasma. Both normal plasma and delipidated plasma were incubated with
NBD-J5 LPS for 60 min at 37°C, and the fluorescence and cholesterol
lipoprotein profiles were determined as described in Materials and
Methods.
|
|
Distribution, saturation, and LPS binding capacity.
To
determine the relative distribution of LPS among the lipoprotein
classes under simulated physiological conditions, we incubated fluorescent LPS with aliquots of whole blood for a preselected (1-h)
time interval and subsequently determined bound LPS by HPGC. We found
that 93 to 99% of the total LPS signal coeluted with the lipoprotein
peaks. The average distributions for all three LPS chemotypes in the
HDL and LDL fractions were found to be essentially similar. HDL showed
the highest, LDL showed intermediate, and VLDL showed the lowest LPS
binding in the LPS concentration range used (Table
1). Heat treatment and clarification of
plasma (60°C, 30 min; 12,000 × g, 20 min) prior to
LPS addition resulted in a normal cholesterol profile but severely
reduced lipoprotein-associated fluorescence (data not shown),
indicating that proteins participate in the loading of the particles
with LPS. A chemotype-dependent variation in VLDL-bound LPS was
apparent. Re595 LPS appears to have a two- or and fourfold higher
preference for VLDL than J5 or O111:B4 LPS, respectively. A relatively
small percentage of the total LPS signal was detected in the plasma
protein fraction. LPS saturation analysis indicated a dose-dependent
binding of O111:B4, J5, or Re595 LPS to the lipoprotein classes (Fig.
5). The total binding capacity of plasma
lipoproteins for all LPS chemotypes examined was found to be in excess
of 200 µg/ml (Fig. 6). HDL shows the
highest binding capacity for LPS and appears to be saturated at an
Re595 LPS concentration of 200 µg/ml of whole blood. Saturation was
not achieved with O111:B4 or J5 LPS concentrations up to 200 µg/ml.
Chemotype-dependent differences in saturation capacity are evident for
VLDL and LDL.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 5.
Chromatographic profiles showing dose response of
LPS-lipoprotein association with three LPS chemotypes, O111:B4, (A), J5
(B), and Re595 (C). All main lipoprotein classes indicated in panel A
apply also to panels B and C. LPS at the concentrations indicated was
incubated for 1 h at 37°C. All chromatograms were corrected for
the inherent fluorescence of plasma components. The data are
representative of a number of independent experiments.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 6.
LPS binding capacities of plasma lipoproteins.
Diagrams of lipoprotein-associated BODIPY-O111:B4 (A), NBD-J5 (B), and
NBD-Re595 (C) LPS show a dose-dependent distribution of LPS on VLDL,
LDL, and HDL in plasma obtained from healthy volunteers. The values
represent the mean ± 1 standard deviation of duplicate results
after correction of the natural fluorescent background of the plasma
components at the excitation and emission wavelengths used. Nonlinear
regression data fit was used to generate the curves.
|
|
Kinetics of LPS binding.
To determine the effect of incubation
time on the LPS distribution among the lipoprotein classes, we added
four different LPS concentrations (Table
2) to plasma samples drawn at various time points and determined the amount of lipoprotein-bound LPS by HPGC
(Fig. 7). The data show that the loading
of lipoprotein particles with O111:B4 LPS progressively increased to 40 min, with no further change in distribution on continued incubation (Fig. 7A). The loading of J5 or Re595 LPS, however, was essentially complete at 10 min, and a redistribution of LPS from HDL to other lipoprotein classes was evident at all LPS concentrations (Table 2). A
progressive decrease in HDL-bound J5 LPS coincided with an increase in
LDL and VLDL signals (Fig. 7B). The 20% reduction in HDL-bound J5 LPS
at 1 h appeared to be compensated for by a 70% increase in LDL-bound
LPS (relative to the amount of bound LPS at 10 min). Similarly, an 18%
reduction in HDL-associated Re595 LPS coincided with a 79% increase in
VLDL-bound LPS relative to the amount of bound LPS at 10 min (Fig. 7C).
Continued incubation with J5 LPS showed that the relative distribution
of this chemotype changes with time, reaching equivalent amounts bound
to LPS on HDL and LDL at 90 min and LDL-bound LPS exceeding HDL-bound
LPS at 2 h. O111:B4, however, showed no decrease in HDL
fluorescence signal within the 2-h incubation period (Table 2).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 7.
LPS binding kinetics of plasma lipoproteins after
incubation of 24 µg of BODIPY-O111:B4 (A), 35 µg of NBD-J5 (B), and
40 µg of NBD-Re595 (C) per ml. After incubation of individual plasma
samples for 10, 20, 40, 60, and 120 min at 37°C, 60 µl of plasma
diluted 1:1 with TBST elution buffer was analyzed by HPGC as described
in the text. All points represent peak areas corrected for inherent
background fluorescence of plasma components at the excitation and
emission wavelengths used. Nonlinear regression data fit was used to
generate the curves. The graphs are representative of one of the four
LPS concentrations used in these experiments which all produced similar
results.
|
|
 |
DISCUSSION |
In this study we present the overall distribution, saturation
analysis, and association kinetics of three biologically active labeled
LPS chemotypes among the major lipoprotein classes, using HPGC for the
quantitation of LPS binding. We examined the binding characteristics of
three different LPS chemotypes representing the range from smooth to
deep rough phenotypes which may all be present in the outer membranes
of wild-type bacterial pathogens, depending on the growth stage and
nutrient source. The LPS of E. coli serotype O111:B4 is a
smooth LPS that contains long O-antigenic polysaccharide side chains,
whereas the E. coli serotype J5 and Salmonella
serovar Typhimurium Re LPS, which contain relatively short
polysaccharide side chains, yield rough and deep-rough colony morphologies, respectively (22). Evaluation of the
resolution of the lipoprotein separation by nephelometric and SDS-PAGE
analyses revealed the presence of apo A-I exclusively in the HDL
fraction and apo B only in the LDL and VLDL fractions. No
apolipoprotein cross-reactivity in any of the lipoprotein classes was
detected with the use of monoclonal antibodies, indicating that
separation of all three lipoprotein classes by size exclusion
chromatography was complete. Lipoproteins isolated by differential
ultracentrifugation generally show a much lower protein content of the
HDL and LDL fractions and no detectable proteins within the VLDL
fraction. Hence, these findings are in accordance with the observation
that ultracentrifugation removes the majority of lipoprotein-associated proteins (18, 20). Kunitake and Kane have demonstrated
that HDL loses substantial amounts of associated apo A-I and probably several other proteins which may be of importance in lipid-LPS transfer
(20). SDS-PAGE analysis of the lipoprotein-associated proteins reveals multiple protein bands in the <200-kDa region (Fig.
3B), confirming that in addition to the major apolipoproteins, as well
as LBP (47), PLTP (33), CETP
(3), and LCAT, known to be associated with HDL, a number
of specific proteins appear to be uniquely associated with all of the
lipoprotein classes.
In this study, we demonstrate that averages of 60, 25, and 12% of the
fluorescent LPS signal were recovered in HDL, LDL, and VLDL fractions
respectively, after incubation for 1 h at 37°C. Compared to
previous results on the LPS distribution among the lipoprotein classes
(36, 44), we demonstrate markedly lower levels of LPS
associated with the plasma protein fraction (Table 1). Total
delipidation of plasma resulted in a complete absence of lipoprotein
classes, as reflected by a 95% reduction in fluorescent LPS signal in
the lipoprotein region of the chromatogram (Fig. 4), indicating that
the binding of LPS by plasma lipoproteins is highly specific.
Additionally, the dramatic decrease in LPS associated with the
lipoprotein classes present in heat-treated, clarified plasma (30 min
at 60°C; 12,000 × g, for 20 min) provides additional
evidence that ancillary proteins are involved in the loading of
lipoproteins with LPS in an active process (unpublished observations).
A relatively higher amount of O111:B4 LPS was recovered in the plasma
protein fraction compared to J5 or Re595 LPS. This is probably a
consequence of a faster loading mechanism of LPS for the more
hydrophobic LPS chemotypes containing shorter O-antigen polysaccharide
chains such as J5 and Re595 (Table 1). Furthermore, we observed that
LPS association is dose dependent, even at LPS concentrations far
exceeding those observed in clinical situations. Nonetheless, these
high LPS concentrations have been used in animal models of endotoxemia,
and it is feasible that comparable or even higher LPS concentrations at
a local focus of infection may be prevalent in the clinical setting.
Our results related to the kinetics of LPS association indicate a
strict chemotype dependence (Fig. 7). The polysaccharide chain length
of LPS is presumably responsible for the velocity of the association:
the shorter the polysaccharide chain, the more hydrophobic the LPS
molecule, in the order O111:B4 > J5 > Re595, and the higher
the apparent affinity of LPS for the lipoprotein phospholipid layer.
During the 2-h incubation, the overall amount of lipoprotein-bound LPS
was nearly unchanged with time, indicating that the initial loading of
LPS was complete within 10 to 20 min and was relatively chemotype
independent. However, the amount of HDL-bound J5 LPS was seen to
decrease with time and was accompanied by a corresponding increase in
LDL-bound LPS. Similarly, a portion of the Re595 LPS fluorescence
signal shifted from HDL to VLDL, indicating a redistribution of these
LPS chemotypes. Because it has been reported that the transport
proteins LBP, CETP, and PLTP are able to bind and transfer LPS to
lipoproteins (16, 47), it is tempting to speculate that
these transfer proteins may also be responsible for the
redistribution of more hydrophobic LPS species with short
polysaccharide chains. It has been documented that rough-type LPS such
as J5 and Re595 is cleared from the circulation more rapidly than
smooth-type LPS such as O111:B4 (37). Therefore, the
observed redistribution toward LDL or VLDL of J5 or Re595 LPS,
respectively, may play a role in the enhanced clearing of lipoproteins
containing these LPS chemotypes from the circulation.
It remains unknown why the inherently high endotoxin binding capacity
of lipoproteins, especially HDL, is not sufficient to diminish the
effects of LPS during severe infection. This may be explained by two
proposed pathways in the kinetics of LPS. First, binding of LPS to
peripheral blood mononuclear cells may be more rapid than the second
mechanism responsible for the loading of the lipoproteins with LPS.
However, as we have demonstrated in this work, approximately 96% of
added LPS is found to be associated with the lipoproteins within 10 to
20 min, a time period probably too short to induce an inflammatory
response as proposed by Netea et al. (30). Further, the
recently described (19) capacity of lipoproteins to
promote the release of LPS from the macrophage surface should favor a
protective role for lipoproteins. Therefore, it is feasible that
after the initial loading phase whereby LPS monomers are actively
transferred from large micellar LPS structures predominantly to HDL,
the subsequent chemotype-dependent redistribution of LPS between the
lipoprotein classes may inadvertently result in the presentation of LPS
to monocytes and macrophages, thus triggering the inflammatory response.
In summary, binding of smooth and rough LPS to lipoprotein
particles is specific and of relatively high affinity. The binding capacity of all LPS chemotypes exceeds concentrations observed in most
clinical situations, and added LPS is mainly associated with HDL
particles. In addition, we describe an LPS chemotype-dependent redistribution of HDL-associated LPS to LDL (J5 LPS) or VLDL (ReLPS). This mechanism may have important implications in the magnitude and
duration of the inflammatory reaction initiated by the presence LPS in
the host.
 |
ACKNOWLEDGMENTS |
We thank K. Bakhtiari and H. P. van Barreveld for excellent
technical assistance and are indebted to B. J. Appelmelk
(Department of Medical Microbiology, Vrije Universiteit, Amsterdam, The
Netherlands) for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Academic Medical
Center, Department of Vascular Medicine, P.O. Box 22660, 1100 DD
Amsterdam, The Netherlands. Phone: 31-20-5663895. Fax: 31-20-5669232. E-mail: h.levels{at}amc.uva.nl.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Alvarez, C., and A. Ramos.
1986.
Lipids, lipoproteins and apoproteins in serum during infection.
Clin. Chem.
32:142-145[Abstract/Free Full Text].
|
| 2.
|
Beamer, L. J.,
S. F. Caroll, and D. Eisenberg.
1997.
Crystal structure of human BPI and two bound phospholipids at 2 Å resolution.
Science
276:1861-1864[Abstract/Free Full Text].
|
| 3.
|
Bolanos-Garcia, V. M.,
M. Soriano-Garcia, and J. Mas-Oliva.
1997.
CETP and exchangeable apoproteins: common features in lipid.
Mol. Cell. Biochem.
175:1-10[CrossRef][Medline].
|
| 4.
|
Bruce, C.,
R. A. Chouinard, and A. Tall.
1998.
Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport.
Annu. Rev. Nutr.
18:297-330[CrossRef][Medline].
|
| 5.
|
Cabana, V. G.,
J. N. Siegel, and S. M. Sabesin.
1989.
Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins.
J. Lipid Res.
30:39-49[Abstract].
|
| 6.
|
Carroll, R. M., and L. L. Rudel.
1983.
Lipoprotein separation and low density lipoprotein molecular weight determination using high performance gel-filtration chromatography.
J. Lipid Res.
24:200-207[Abstract].
|
| 7.
|
Cham, B. E., and B. R. Knowles.
1976.
A solvent system for delipidation of plasma or serum without protein precipitation.
J. Lipid Res.
17:176-181[Abstract].
|
| 8.
|
Cheung, M. C., and A. C. Wolf.
1988.
Differential effect of ultracentrifugation on apolipoprotein A-I-containing lipoprotein subpopulations.
J. Lipid Res.
29:15-25[Abstract].
|
| 9.
|
Eggesbo, J. B.,
T. Lyberg,
T. Aspelin,
I. Hjermann, and P. Kierulf.
1996.
Different binding of 125I-LPS to plasma proteins from persons with high or low HDL.
Scand. J. Clin. Lab. Investig.
56:533-543[Medline].
|
| 10.
|
Emancipator, K.,
G. Sako, and R. J. Elin.
1992.
In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins.
Infect. Immun.
60:596-601[Abstract/Free Full Text].
|
| 11.
|
Fainaru, M.,
R. J. Havel, and K. Imaizumi.
1977.
Apoprotein content of plasma lipoproteins of the rat separated by gel chromatography or ultracentrifugation.
Biochem. Med.
17:347-355[CrossRef][Medline].
|
| 12.
|
Feingold, K. R.,
J. L. Funk,
A. H. Moser,
J. K. Shigenaga,
J. H. Rapp, and C. Grunfeld.
1995.
Role for circulating lipoproteins in protection from endotoxin toxicity.
Infect. Immun.
63:2041-2046[Abstract].
|
| 13.
|
Flegel, W. A.,
A. Wölpl,
H. Northhoff, and D. N. Männel.
1989.
Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins.
Infect. Immun.
57:2237-2245[Abstract/Free Full Text].
|
| 14.
|
Gordon, B. R.,
T. S. Parker,
D. M. Levine,
S. D. Saal,
J. C. L. Wang,
B. J. Sloan,
P. S. Barie, and A. L. Rubin.
1996.
Low lipid concentrations in critical illness: implications for preventing and treating endotoxemia.
Crit. Care Med.
24:584-589[CrossRef][Medline].
|
| 15.
|
Grunfeld, C., and K. R. Feingold.
1996.
Regulation of lipid metabolism by cytokines during host defence.
Nutrition
12:24-26.
|
| 16.
|
Hailman, E.,
J. J. Albers,
G. Wolfbauer,
A. Tu, and S. D. Wright.
1996.
Neutralisation and transfer of lipopolysaccharide by phospholipid transfer protein.
J. Biol. Chem.
271:12172-12178[Abstract/Free Full Text].
|
| 17.
|
Irwin, D.,
P. A. O'Looney,
E. Quinet, and G. V. Vahouny.
1984.
Application of SDS gradient polyacrylamide slab gel electrophoresis to analysis of apolipoprotein mass and radioactivity of rat lipoproteins.
Atherosclerosis
53:163-172[CrossRef][Medline].
|
| 18.
|
Kane, J., and S. T. Kunitake.
1999.
Isolation of plasma lipoproteins by ultracentrifugation and immunosorption, p. 463-471.
In
D. J. Betteridge, D. R. Illingworth, and J. Shepherd (ed.), Lipoproteins in health and disease. Arnold, London, England.
|
| 19.
|
Kitchens, R. L.,
G. Wolfbauer,
J. J. Albers, and R. S. Munford.
2000.
Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface.
J. Biol. Chem.
274:34116-34122[Abstract/Free Full Text].
|
| 20.
|
Kunitake, S. T., and J. Kane.
1982.
Factors affecting the integrity of high density lipoproteins in the ultracentrifuge.
J. Lipid Res.
23:936-940[Abstract].
|
| 21.
|
Lee, C. H., and C. M. Tsai.
1999.
Quantification of bacterial lipopolysaccharides by the Purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation.
Anal. Biochem.
267:161-168[CrossRef][Medline].
|
| 22.
|
Martin, G.,
H. Ghabrial,
D. J. Morgan,
R. A. Smallwood, and R. B. Sewell.
1992.
High-performance liquid chromatography method to resolve and determine lipopolysaccharide sub-groups of Escherichia coli endotoxin in isolated perfused rat liver perfusate.
J. Chromatogr.
574:205-211[Medline].
|
| 23.
|
Marz, W.,
R. Siekmeier,
H. Scharnagl,
U. B. Seiffert, and W. Gross.
1993.
Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins.
Clin. Chem.
39:2276-2281[Abstract].
|
| 24.
|
Mathison, J.,
P. Tobias,
E. Wolfson, and R. Ulevitch.
1991.
Regulatory mechanisms of host responsiveness to endotoxin (lipopolysaccharide).
Pathobiology
59:185-188[Medline].
|
| 25.
|
Morrison, D. C., and L. Leive.
1975.
Fractions of lipopolysaccharide from Escherichia coli O111:B4 prepared by two extraction procedures.
J. Biol. Chem.
250:2911-2919[Abstract/Free Full Text].
|
| 26.
|
Morrissey, J. H.
1981.
Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity.
Anal. Biochem.
117:307-310[CrossRef][Medline].
|
| 27.
|
Munford, R. S., and J. M. Dietschy.
1985.
Effects of specific antibodies, hormones and lipoproteins on bacterial lipopolysaccharides injected into rat.
J. Infect. Dis.
152:177-184[Medline].
|
| 28.
|
Munford, R. S.,
C. L. Hall, and J. M. Dietschy.
1981.
Binding of Salmonella typhimurium lipopolysaccharides to rat high-density lipoproteins.
Infect. Immun.
49:835-843.
|
| 29.
|
Myc, A.,
J. Buck,
J. Gonin,
B. Reynolds,
U. Hammerling, and D. Emanuel.
1997.
The level of lipopolysaccharide-binding protein is significantly increased in plasma patients with the systemic inflammation response syndrome.
Clin. Diagn. Lab. Immunol.
4:113-116[Abstract].
|
| 30.
|
Netea, M. G.,
P. N. M. Demacker,
B. J. Kullberg,
L. E. H. Jacobs,
T. J. G. Verver-Jansen,
O. C. Boerman,
A. F. Slalenhoef, and J. W. M. van der Meer.
1998.
Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur.
Cytokine
10:766-772[CrossRef][Medline].
|
| 31.
|
Northhoff, H.,
W. A. Flegel,
R. Yurttas, and C. Weinstock.
1992.
The role of lipoproteins in the inactivation of endotoxin by serum.
Infus. Ther.
19:202-203.
|
| 32.
|
Park, C. T., and S. D. Wright.
1996.
Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related protein.
J. Biol. Chem.
271:18054-18060[Abstract/Free Full Text].
|
| 33.
|
Pussinen, P. J.,
M. Jauhiainen,
J. Metso,
L. E. Pyle,
Y. L. Marcel,
N. H. Fidge, and C. Ehnholm.
1998.
Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of PLTP binding domain in the terminal region of apo A-I.
J. Lipid Res.
39:152-161[Abstract/Free Full Text].
|
| 34.
|
Qureshi, N.,
K. Takayama,
P. Mascagni,
J. Honovich,
R. Wong, and R. J. Cotter.
1988.
Complete structural determination of lipopolysaccharide obtained from deep rough mutant of Escherichia coli.
J. Biol. Chem.
263:11971-11976[Abstract/Free Full Text].
|
| 35.
|
Read, T. E.,
H. W. Harris,
C. Grunfeld,
K. R. Feingold,
M. C. Calhoun,
J. P. Kane, and J. H. Rapp.
1993.
Chylomicrons enhance endotoxin excretion in bile.
Infect. Immun.
61:3496-3502[Abstract/Free Full Text].
|
| 36.
|
Roth, R. I.,
F. C. Levin, and J. Levin.
1993.
Distribution of bacterial endotoxin in human and rabbit blood and effects of stroma-free hemoglobin.
Infect. Immun.
61:3209-3215[Abstract/Free Full Text].
|
| 37.
|
Salomao, R.,
O. Rigato,
A. C. Pignatari,
M. A. Freudenberg, and C. Galanos.
1999.
Bloodstream infections: epidemiology, pathophysiology and therapeutic perspectives.
Infection
27:1-11[Medline].
|
| 38.
|
Schichtling, E.,
T. Aspelin, and T. Lyberg.
1996.
Interactions of endotoxin with human blood cells and serum proteins.
Scand. J. Clin. Lab. Investig.
56:167-176[Medline].
|
| 39.
|
Tadey, T., and W. C. Purdy.
1995.
Chromatographic techniques for the isolation and purification of lipoproteins.
J. Chromatogr. B
671:237-253[CrossRef][Medline].
|
| 40.
|
Tallis, G. A.,
M. D. S. Shephard, and M. J. Whiting.
1994.
Lipoprotein profiling by high performance gel chromatography.
Clin. Chim. Acta
228:171-179[CrossRef][Medline].
|
| 41.
|
Tobias, P. S.,
K. Soldau,
J. A. Gegner,
D. Mintz, and R. J. Ulevitch.
1995.
Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14.
J. Biol. Chem.
270:10482-10488[Abstract/Free Full Text].
|
| 42.
|
Troelstra, A.,
P. Antal-Szalmas,
L. A. Graaf-Miltenburg,
A. J. Weersink,
J. Verhoef,
K. P. van Kessel, and J. A. van Strijp.
1997.
Saturable CD14-dependent binding of fluorescein-labeled lipopolysaccharide to human monocytes.
Infect. Immun.
65:2272-2277[Abstract].
|
| 43.
|
van Gent, T., and A. van Tol.
1990.
Automated gel permeation chromatography of plasma lipoproteins by preparative fast protein liquid chromatography.
J. Chromatogr. A
572:433-441.
|
| 44.
|
Van Lenten, B. J.,
A. M. Fogelman,
M. E. Haberland, and P. A. Edwards.
1986.
The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide.
Proc. Natl. Acad. Sci. USA
83:2704-2708[Abstract/Free Full Text].
|
| 45.
|
Wang, P. Y.,
R. L. Kitchens, and R. S. Munford.
1996.
Bacterial lipopolysaccharide binds to CD14 in low-density domains of the monocyte-macrophage plasma membrane.
J. Inflamm.
47:126-137.
|
| 46.
|
Westerlund, J., and Z. Yao.
1995.
Elution of lipoprotein fractions containing apolipoproteins E and A-I in size on superose 6 columns is sensitive to mobile phase pH and ionic strength.
J. Chromatogr.A
718:59-66[CrossRef].
|
| 47.
|
Wurfel, M. M.,
S. T. Kunitake,
H. Lichenstein,
J. P. Kane, and S. D. Wright.
1994.
Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS.
J. Exp. Med
180:1025-1035[Abstract/Free Full Text].
|
| 48.
|
Wurfel, M. M., and S. D. Wright.
1997.
Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers.
J. Immunol.
158:3925-3934[Abstract].
|
| 49.
|
Yu, B., and S. D. Wright.
1996.
Catalytic properties of lipopolysaccharide (LPS) binding protein.
J. Biol. Chem.
271:4100-4105[Abstract/Free Full Text].
|
Infection and Immunity, May 2001, p. 2821-2828, Vol. 69, No. 5
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.2821-2828.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kallio, K.A. E., Buhlin, K., Jauhiainen, M., Keva, R., Tuomainen, A. M., Klinge, B., Gustafsson, A., Pussinen, P. J.
(2008). Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immunity
14: 247-253
[Abstract]
-
Westerterp, M., Berbee, J. F.P., Pires, N. M.M., van Mierlo, G. J.D., Kleemann, R., Romijn, J. A., Havekes, L. M., Rensen, P. C.N.
(2007). Apolipoprotein C-I Is Crucially Involved in Lipopolysaccharide-Induced Atherosclerosis Development in Apolipoprotein E Knockout Mice. Circulation
116: 2173-2181
[Abstract]
[Full Text]
-
Thaveeratitham, P., Plengpanich, W., Naen-Udorn, W., Patumraj, S., Khovidhunkit, W.
(2007). Effects of human apolipoprotein A-I on endotoxin-induced leukocyte adhesion on endothelial cells in vivo and on the growth of Escherichia coli in vitro. Innate Immunity
13: 58-64
[Abstract]
-
Kontush, A., Chapman, M. J.
(2006). Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis. Pharmacol. Rev.
58: 342-374
[Abstract]
[Full Text]
-
Aspichueta, P., Perez-Agote, B., Perez, S., Ochoa, B., Fresnedo, O.
(2006). Impaired response of VLDL lipid and apoB secretion to endotoxin in the fasted rat liver. Innate Immunity
12: 181-191
[Abstract]
-
Francone, O. L., Royer, L., Boucher, G., Haghpassand, M., Freeman, A., Brees, D., Aiello, R. J.
(2005). Increased Cholesterol Deposition, Expression of Scavenger Receptors, and Response to Chemotactic Factors in Abca1-Deficient Macrophages. Arterioscler. Thromb. Vasc. Bio.
25: 1198-1205
[Abstract]
[Full Text]
-
Berbee, J. F.P., Havekes, L. M., Rensen, P. C.N.
(2005). Apolipoproteins modulate the inflammatory response to lipopolysaccharide. Innate Immunity
11: 97-103
[Abstract]
-
German, J B., Dillard, C. J
(2004). Saturated fats: what dietary intake?. Am. J. Clin. Nutr.
80: 550-559
[Abstract]
[Full Text]
-
Bocharov, A. V., Baranova, I. N., Vishnyakova, T. G., Remaley, A. T., Csako, G., Thomas, F., Patterson, A. P., Eggerman, T. L.
(2004). Targeting of Scavenger Receptor Class B Type I by Synthetic Amphipathic {alpha}-Helical-containing Peptides Blocks Lipopolysaccharide (LPS) Uptake and LPS-induced Pro-inflammatory Cytokine Responses in THP-1 Monocyte Cells. J. Biol. Chem.
279: 36072-36082
[Abstract]
[Full Text]
-
Khovidhunkit, W., Kim, M.-S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R., Grunfeld, C.
(2004). Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host. J. Lipid Res.
45: 1169-1196
[Abstract]
[Full Text]
-
Kaneko, K., Ueda, R., Kawata, T., Ishizaka, S., Yoshimura, T.
(2004). LPS binding protein does not participate in the pharmacokinetics of E5564. Innate Immunity
10: 185-194
[Abstract]
-
Kitchens, R. L., Thompson, P. A., Munford, R. S., O'Keefe, G. E.
(2003). Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J. Lipid Res.
44: 2339-2348
[Abstract]
[Full Text]
-
Walton, K. A., Cole, A. L., Yeh, M., Subbanagounder, G., Krutzik, S. R., Modlin, R. L., Lucas, R. M., Nakai, J., Smart, E. J., Vora, D. K., Berliner, J. A.
(2003). Specific Phospholipid Oxidation Products Inhibit Ligand Activation of Toll-Like Receptors 4 and 2. Arterioscler. Thromb. Vasc. Bio.
23: 1197-1203
[Abstract]
[Full Text]
-
Bisoendial, R. J., Hovingh, G. K., Levels, J. H.M., Lerch, P. G., Andresen, I., Hayden, M. R., Kastelein, J. J.P., Stroes, E. S.G.
(2003). Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein. Circulation
107: 2944-2948
[Abstract]
[Full Text]
-
Vishnyakova, T. G., Bocharov, A. V., Baranova, I. N., Chen, Z., Remaley, A. T., Csako, G., Eggerman, T. L., Patterson, A. P.
(2003). Binding and Internalization of Lipopolysaccharide by Cla-1, a Human Orthologue of Rodent Scavenger Receptor B1. J. Biol. Chem.
278: 22771-22780
[Abstract]
[Full Text]
-
Kitchens, R. L., Thompson, P. A.
(2003). Impact of sepsis-induced changes in plasma on LPS interactions with monocytes and plasma lipoproteins: roles of soluble CD14, LBP, and acute phase lipoproteins. Innate Immunity
9: 113-118
[Abstract]
-
Opal, S. M.
(2002). The clinical relevance of endotoxin in human sepsis: a critical analysis. Innate Immunity
8: 473-476
[Abstract]
-
van der Vliet, H. N., Sammels, M. G., Leegwater, A. C. J., Levels, J. H. M., Reitsma, P. H., Boers, W., Chamuleau, R. A. F. M.
(2001). Apolipoprotein A-V. A NOVEL APOLIPOPROTEIN ASSOCIATED WITH AN EARLY PHASE OF LIVER REGENERATION. J. Biol. Chem.
276: 44512-44520
[Abstract]
[Full Text]